Spots Global Cancer Trial Database for M6620 First in Human Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: M6620 First in Human Study
Official Title: An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Study ID: NCT02157792
Conditions
Study Description
Brief Summary: An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics (PK) of M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic Arizona, Phoenix, Arizona, United States
Sharp Memorial Hospital, San Diego, California, United States
, Stanford, California, United States
Rocky Mountain Cancer Centers, LLP, Denver, Colorado, United States
Emory University, Atlanta, Georgia, United States
Northwestern Center for Clinical Research, Chicago, Illinois, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Breslin Cancer Center, Lansing, Michigan, United States
University Of Minnesota Hospital, Minneapolis, Minnesota, United States
Mayo Clinic - Rochester, Rochester, Minnesota, United States
Washington University in St. Louis, Saint Louis, Missouri, United States
Hackensack University Medical Center PARTNER, Hackensack, New Jersey, United States
Long Island Jewish Medical Center - Monter Cancer Center, Lake Success, New York, United States
University Hospitals Case Medical Center - Case Comprehensive Cancer Center at, Cleveland, Ohio, United States
OSU - James Comprehensive Cancer Center - Division of Hematology, Columbus, Ohio, United States
Greenville Health System, Greenville, South Carolina, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
US Oncology - Texas Oncology-Midtown - Austin Midtown, Austin, Texas, United States
Texas Oncology, P.A., Dallas, Texas, United States
University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics - Partner, Houston, Texas, United States
Texas Oncology San Antonio Medical Cente, San Antonio, Texas, United States
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
Virginia Oncology Associates - Hampton, Norfolk, Virginia, United States
Northwest Cancer Specialists , P.C., Vancouver, Washington, United States
Freeman Hospital - PARENT, Newcastle Upon Tyne, England, United Kingdom
Churchill Hospital - PARENT, Oxford, England, United Kingdom
Beatson West of Scotland Cancer Centre - Dept of Medical Oncology, Glasgow, Scotland, United Kingdom
Royal Marsden Hospital - Dept of Oncology, Sutton, Surrey, United Kingdom
Guy's Hospital - PARENT, London, , United Kingdom
Sarah Cannon Research Institute UK, London, , United Kingdom
The Christie - Dept of Oncology, Manchester, , United Kingdom
Contact Details
Name: Medical Responsible
Affiliation: EMD Serono Research & Development Institute, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
